NCCN 2018 Congress Series™: Breast Cancer with Updates from 2017 San Antonio Breast Cancer Symposium

Chicago, IL US
February 9, 2018

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The treatment of breast cancer is rapidly evolving. Results from numerous clinical trials continue to expand new therapeutic options, treatment and risk reduction strategies, and diagnostic/prognostic tools. Health care professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for Breast Cancer and NCCN’s educational interventions to increase knowledge and bridge the gaps between knowledge and competence.

This congress will provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Breast Cancer to ensure that oncology health care professionals have a clear understanding of the current standard of care for patients with breast cancer and to assist them with formulating breast cancer management strategies.

Featured sessions at this program will include updates on information presented at the 2017 San Antonio Breast Cancer Symposium® (SABCS). This update has become the highlight of this annual congress hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University each year.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurses, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

Breast Cancer Screening
•    Outline the risks and benefits of routine screening with mammography in women between the ages of 40 to 49.
•    Discuss screening recommendations for women with high risk of developing breast cancer.

Barriers to the Coordination of Cancer Care
•    Recognize common barriers encountered during planning and delivery of care for patients with breast cancer.
•    Counsel patients with breast cancer about the roles and responsibilities of the individuals in their multidisciplinary care team.

Surgical Management of the Axilla in Early Stage Breast Cancer, Including SABCS Updates
•    Individualize the surgical management of the axilla using an evidence-based approach.
•    Discuss new and emerging data for surgical treatment of patients with early stage breast cancer.

NCCN Guidelines® Updates: Early Stage Breast Cancer
•    Summarize recommendations based on tumor margin status after breast conservation for DCIS and early stage invasive breast cancer.
•    Review recent NCCN Guidelines® updates to radiation therapy recommendations for DCIS and early stage invasive breast cancer.

Role of Biomarkers and Molecular Assays in the Management of Breast Cancer
•    Compare the benefits and limitations of available multigene assays and determine their effectiveness in assessment of risk of recurrence.
•    Select the appropriate assay to individualize adjuvant systemic therapy recommendations.

Adjuvant and Neoadjuvant Therapies, Including SABCS Updates
•    Recognize key patient and clinical factors that influence selection of systemic neoadjuvant and adjuvant treatment.
•    Discuss clinical data of new and emerging systemic therapy options with patients with early stage breast cancer.

Surveillance of Patients with Early Stage and Advanced Disease
•    Optimize the various strategies used for surveillance and follow-up after primary treatment in patients with early stage breast cancer.
•    Order appropriate tests to assess response to treatment in patients with metastatic disease.

Management of Metastatic Breast Cancer, Including SABCS Updates
•    Select evidence-based treatment options for patients with advanced breast cancer based on hormone and HER2 receptor status.
•    Outline new and emerging therapeutic options for patients with advanced breast cancer.

Additional information
Supporters: 

This activity is supported by educational grants from Eisai; Genomic Health, Inc.; Lilly; Novartis; and Pfizer.

Course summary
Available credit: 
  • 5.00 ACPE contact hours
  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 ANCC contact hours
  • 5.00 ABIM MOC
  • 5.00 Participation
Course opens: 
02/08/2018
Course expires: 
04/15/2018
Event starts: 
02/09/2018 - 7:45am
Event ends: 
02/09/2018 - 3:30pm
Cost:
$0.00
Prentice Women's Hospital
250 East Superior Street
Conference Room L, 3rd Floor
Chicago, IL 60611
United States

Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions  

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.  NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses no relevant financial relationships:

Benjamin O. Anderson, MD
Harold J. Burstein, MD, PhD
Lisa E. Flaum, MD
William J. Gradishar, MD
Meena S. Moran, MD

The faculty listed below discloses the following relevant financial relationships:

Therese B. Bevers, MD
Menssana Research, Inc.: Grant/Research Support
Toray Industries, Inc.: Grant/Research Support

Matthew P. Goetz, MD
Biotheranostics: Scientific Advisor
Eisai Inc.: Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Myriad Genetic Laboratories, Inc.: Scientific Advisor
Pfizer Inc.: Grant/Research Support
Sermonix Pharmaceuticals: Consulting Fees, Honoraria; Scientific Advisor

Lee S. Schwartzberg, MD
Bristol-Myers Squibb Company: Scientific Advisor
Genentech, Inc.: Consulting Fees, Honoraria
Genomic Health, Inc.: Consulting Fees, Honoraria
Pfizer Inc.: Consulting Fees, Honoraria

Julia R. Trosman, PhD, MBA
Genentech, Inc.: Consulting Fees, Honoraria
Pfizer Inc.: Grant/Research Support

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Kimberly Bayer; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (Employed by NCCN until 10/30/17)

The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:

Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mary Anne Bergman; Ellen Erkess; Rashmi Kumar, PhD; Dorothy A. Shead, MS

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties (MOC)
Through the American Board of Medical Specialties (“ABMS”) MOC Initiative to create a wide array of Maintenance of Certification (“MOC”) Activities through the ABMS MOC Directory, NCCN 2018 Congress Series™ – Breast Cancer with Updates from the 2017 San Antonio Breast Cancer Symposium has met the MOC requirements as a MOC Part II CME Activity (apply toward general CME requirement) by the following ABMS Member Boards:

MOC Part II CME Activity
Pathology
Radiology

Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement (only). Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 5 hours of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 5 contact hours.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 5 contact hours (0.5 CEUs) of continuing education credit. UAN: 0836-0000-18-021-L01-P

Available Credit

  • 5.00 ACPE contact hours
  • 5.00 AMA PRA Category 1 Credit™
  • 5.00 ANCC contact hours
  • 5.00 ABIM MOC
  • 5.00 Participation

Accreditation Period

Course opens: 
02/08/2018
Course expires: 
04/15/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing